Sepsis is a life-threatening response to bacteria in the bloodstream. It is responsible for 1.6 million hospitalizations and nearly 200,000 deaths per year in the United States.1,2 It costs the U.S. healthcare system more than $20 billion per year3 and is commonly complicated by antimicrobial resistance.
Earlier diagnosis of sepsis leads to better outcomes, as the risk of death increases by 7.6% every hour that appropriate treatment is delayed. Targeted therapy based on identification of causative bacteria and antibacterial resistance is the most effective sepsis treatment.4
Conventional diagnostic methods require 48 to 96 hours to deliver bacterial identification and resistance determination. In the meantime, patients are treated with broad-based antibiotics that are often unnecessary or inappropriate and frequently toxic.
Tests run on the VERIGENE platform are designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract.
VERIGENE provides cost-effective bacterial identification and antibiotic resistance determination directly from positive blood culture bottles up to 48 hours faster than conventional methods.5 The Gram-Positive Blood Culture (BC-GP) test provides 15 different targets, and the Gram-Negative Blood Culture (BC-GN) test provides 14 different targets.
VERIGENE enables an earlier shift from empiric to targeted antibiotic treatment6 and differentiates potential blood culture contaminants. As a result, the VERIGENE System delivers better outcomes, improved patient care, and true antibiotic stewardship, all at a lower cost.
The VERIGENE® Gram-Positive Blood Culture Test (BC-GP) identifies genus, species, and genetic resistance determinants for a broad panel of gram-positive bacteria directly from positive blood culture bottles.
The VERIGENE® Gram-Negative Blood Culture Test (BC-GN) identifies genus, species, and genetic resistance determinants for a broad panel of gram-negative bacteria directly from positive blood culture bottles.
Luminex Corporation is a partner of Sepsis Alliance
For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.